Share
News

Two Countries Restrict Use of AstraZeneca's COVID Vaccine as Concerning Reports Emerge

Share

German health officials agreed Tuesday to restrict the use of AstraZeneca’s COVID-19 vaccine in people under 60 amid fresh concern over unusual blood clots reported in a small number of those who received the shots.

Health Minister Jens Spahn and state officials agreed unanimously to only give the vaccine to people aged 60 or older, unless they belong to a high-risk category for serious illness from COVID-19 and have agreed with their doctor to take the vaccine.

The move follows the recommendations of Germany’s independent vaccine panel and comes after the country’s medical regulator released new data showing a rise in reported cases of an unusual form of blood clot in the head — known as sinus vein thrombosis — in recent recipients of the AstraZeneca vaccine.

On Monday, Canada suspended use of the vaccine in people under 55, citing concerning new data from Europe.

“There is substantial uncertainty about the benefit of providing AstraZeneca COVID-19 vaccines to adults under 55 given the potential risks,” Dr. Shelley Deeks, vice chair of Canada’s National Advisory Committee on Immunization, said.

Trending:
Kamala Harris Gets Ice-Cold Reception on Trip to Promote Biden's Massive Spending Plan

Deeks said the updated recommendations come amid new data from Europe that suggests the risk of blood clots is now potentially as high as one in 100,000.

The news is a further blow to the vaccine, whose rollout has been plagued with missteps.

It comes less than two weeks after the EU drug regulator said the vaccine does not increase the overall incidence of blood clots following a similar scare.

The European Medicines Agency said at the time that the benefits of vaccination outweigh the risks, but it could not rule out a link between the shot and some unusual kinds of clots, and recommended adding a warning about possible rare side effects.

Would you be willing to receive AstraZeneca's COVID-19 vaccine?

Several German regions — including the capital Berlin and the country’s most populous state, North Rhine-Westphalia — had already suspended use of the shots in younger people earlier Tuesday.

That decision came after the country’s medical regulator said its tally of the rare blood clots reported by March 29 had increased to 31 out of some 2.7 million doses administered in Germany so far.

Nine of the people died and all but two of the cases involved women, who were aged 20 to 63, the Paul Ehrlich Institute said.

In a statement ahead of the announcement, AstraZeneca said tens of millions of people worldwide have received its vaccines, and noted that the EU regulator and the World Health Organization concluded that the benefits of the shot outweigh the risks.

The company said it would continue to work with German authorities to address any questions they might have, while also analyzing its own records to find out whether the rare blood clots reported occur more commonly “than would be expected naturally in a population of millions of people.”

Related:
FDA Expected to Approve Pfizer Vaccines for Children as Young as 12 Within a Week

The suspensions come as Germany, along with other European countries, is scrambling to speed up its vaccination effort, which lags far behind those in Britain and the United States.

By Monday, some 13.2 million people in the country had received at least one dose of vaccine, while nearly 4 million had received both shots.

Use of the AstraZeneca vaccine was temporarily halted in several European countries earlier this month over concerns about the rare blood clots. After a review by the European Medicines Agency, most European Union countries, including Germany, resumed use of the vaccine on March 19.

Scientists at the University of Greifswald, Germany, this week published the results of their investigation into the possible causes of the blood clots, saying the condition is similar to a side effect seen in some patients who receive the blood thinning medication heparin.

The study doesn’t provide a conclusive explanation for why some people vaccinated with the AstraZeneca shot develop the rare blood clots.

Alice Assinger, a specialist in vascular diseases and blood clot research at the Medical University of Vienna, said there is a treatment for the rare clots.

The leader of the Norwegian Association for General Practice, Marte Kvittum Tangen, told Norwegian broadcaster NRK last week that while “people clearly say that they do not want the AstraZeneca vaccine. There is a lot of uncertainty and skepticism.”

Initially, several European countries hesitated to give the AstraZeneca shot to older people, citing a lack of data from the company about the vaccine’s effectiveness in those aged 65 and over. Subsequent studies showing it works in older people prompted most countries to approve it for that age group.

The Western Journal has reviewed this Associated Press story and may have altered it prior to publication to ensure that it meets our editorial standards.

Truth and Accuracy

Submit a Correction →



We are committed to truth and accuracy in all of our journalism. Read our editorial standards.

Tags:
, , , , , , , ,
Share
The Associated Press is an independent, not-for-profit news cooperative headquartered in New York City. Their teams in over 100 countries tell the world’s stories, from breaking news to investigative reporting. They provide content and services to help engage audiences worldwide, working with companies of all types, from broadcasters to brands.
The Associated Press was the first private sector organization in the U.S. to operate on a national scale. Over the past 170 years, they have been first to inform the world of many of history's most important moments, from the assassination of Abraham Lincoln and the bombing of Pearl Harbor to the fall of the Shah of Iran and the death of Pope John Paul.

Today, they operate in 263 locations in more than 100 countries relaying breaking news, covering war and conflict and producing enterprise reports that tell the world's stories.
Location
New York City




Conversation